Academic literature on the topic 'Dox-Induced Cardiotoxicity'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dox-Induced Cardiotoxicity.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Dox-Induced Cardiotoxicity":
Sumneang, Natticha, Pongpan Tanajak, and Thura Tun Oo. "Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity." Molecules 28, no. 11 (May 24, 2023): 4294. http://dx.doi.org/10.3390/molecules28114294.
Ammar, El-Sayed M., Shehta A. Said, Ghada M. Suddek, and Sally L. El-Damarawy. "Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats." Canadian Journal of Physiology and Pharmacology 89, no. 4 (April 2011): 269–76. http://dx.doi.org/10.1139/y11-020.
Hamaamin, Karmand Salih, and Tavga Ahmed Aziz. "Doxorubicin-Induced Cardiotoxicity: Mechanisms and Management." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 3 (December 10, 2022): 87–97. http://dx.doi.org/10.54133/ajms.v3i.90.
Zheng, Dong, Yi Zhang, Ming Zheng, Ting Cao, Grace Wang, Lulu Zhang, Rui Ni, et al. "Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity." Clinical Science 133, no. 13 (July 2019): 1505–21. http://dx.doi.org/10.1042/cs20181022.
Zhang, Wei, Zhixing Fan, Fengyuan Wang, Lin Yin, Jinchun Wu, Dengke Li, Siwei Song, Xi Wang, Yanhong Tang, and Congxin Huang. "Tubeimoside I Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating SIRT3." Oxidative Medicine and Cellular Longevity 2023 (January 14, 2023): 1–23. http://dx.doi.org/10.1155/2023/9966355.
Mao, Jin Ning, Ai Jun Li, Liang Ping Zhao, Lan Gao, Wei Ting Xu, Xiao Su Hong, Wen Ping Jiang, and Jian Chang Chen. "PEG-PLGA Nanoparticles Entrapping Doxorubicin Reduced Doxorubicin-Induced Cardiotoxicity in Rats." Advanced Materials Research 912-914 (April 2014): 263–68. http://dx.doi.org/10.4028/www.scientific.net/amr.912-914.263.
Maneechote, Chayodom, Siriporn C. Chattipakorn, and Nipon Chattipakorn. "Recent Advances in Mitochondrial Fission/Fusion-Targeted Therapy in Doxorubicin-Induced Cardiotoxicity." Pharmaceutics 15, no. 4 (April 7, 2023): 1182. http://dx.doi.org/10.3390/pharmaceutics15041182.
Kitakata, Hiroki, Jin Endo, Hidehiko Ikura, Hidenori Moriyama, Kohsuke Shirakawa, Yoshinori Katsumata, and Motoaki Sano. "Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis." International Journal of Molecular Sciences 23, no. 3 (January 26, 2022): 1414. http://dx.doi.org/10.3390/ijms23031414.
da Cunha Menezes Souza, Leonardo, Meng Chen, Yuji Ikeno, Daisy Maria Fávero Salvadori, and Yidong Bai. "The implications of mitochondria in doxorubicin treatment of cancer in the context of traditional and modern medicine." Traditional Medicine and Modern Medicine 03, no. 04 (December 2020): 239–54. http://dx.doi.org/10.1142/s2575900020300076.
Jiang, Lai, Yanping Gong, Yida Hu, Yangyang You, Jiawu Wang, Zhetao Zhang, Zeyuan Wei, and Chaoliang Tang. "Peroxiredoxin-1 Overexpression Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Oxidative Stress and Cardiomyocyte Apoptosis." Oxidative Medicine and Cellular Longevity 2020 (July 29, 2020): 1–11. http://dx.doi.org/10.1155/2020/2405135.
Dissertations / Theses on the topic "Dox-Induced Cardiotoxicity":
Mammadova, Aynura. "The role of MEIS inhibitors in cardiac regeneration and protection." Electronic Thesis or Diss., Strasbourg, 2024. http://www.theses.fr/2024STRAJ006.
The TALE-type homeobox gene MEIS1 has been identified as a critical factor in controlling the cell cycle arrest of cardiomyocytes, presenting itself as an attractive target for therapy. Our latest investigations have revealed the potential of MEIS1 suppression to promote the regeneration of cardiomyocytes. Further experiments with neonatal cardiomyocytes showed that two innovative small molecules, MEISi-1 and MEISi-2, enhanced the proliferation (Ph3+TnnT cells) and cytokinesis (AuroraB+TnnT cells) of these cells. Suppressing MEIS1 activity resulted in the diminished expression of its target genes and the inhibitors of cyclin-dependent kinases. Additionally, this research extended to cultivating human induced pluripotent stem cells (hiPSCs) into cardiomyocytes to examine the impact of MEIS1 suppression, which notably did not compromise their viability. Intriguingly, short-term and long-term treatment with MEISi in hiPSCs led to significant elevation in essential cardiac-specific gene expression, notably influencing cardiac mesoderm and progenitor cells, and positioning MEIS1 inhibitors as crucial modulators of cardiac gene expression. Our findings indicate that MEIS inhibitors can provide protection against the acute cardiotoxic effects of doxorubicin (DOX) in Wistar rats, as evidenced by the maintained structure of cardiac tissue and unchanged levels of fibrosis or collagen. qPCR analyses further confirmed the upregulation of cardiac progenitor genes and a balance in anti-apoptotic and ROS-related gene expression, hinting at the protective role of MEIS inhibitors against DOX-induced damage without influencing fibrosis. These results highlight the therapeutic potential of MEIS inhibitors in regenerative cardiology, suggesting their utility in enhancing cardiomyocyte renewal and offering protection against cardiotoxicity
Conference papers on the topic "Dox-Induced Cardiotoxicity":
Tao, Rong-Hua, Masato Kobayashi, Fei Wang, Yuanzheng Yang, and Eugenie S. Kleinerman. "Abstract 5422: Dissecting the mechanism of exercise-mediated protection of Dox-induced cardiotoxicity." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5422.